ATNXQ — Athenex Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.13m
- $74.91m
- $102.82m
U.S. STOCKS ON THE MOVE-Iterum Therapeutics PLC, Titan Machinery Inc, Volcon Inc
Diagnostics Inc
Athenex to sell China business, shares rise
Athenex up on sale of certain rights for skin disorder drug
Brief: Athenex Announces Sale Of Revenues From U.S. And European Royalty And Milestone Interests In Klisyri® (Tirbanibulin) To Sagard Healthcare Partners And Oaktree
Brief: Athenex Announces Collaboration With Merck To Evaluate Oraxol Plus Keytruda In Patients With NSCLC
Athenex Inc reports results for the quarter ended in March - Earnings Summary
Brief: Athenex Inc Reports Q1 Product Sales Of $29.0 Mln, Up 42% Year-Over-Year
Athenex Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Athenex Presents Interim Data From Study Of KUR-502 In Lymphoma And Leukemia
Brief: Athenex Inc Says There Is Substantial Doubt About Co's Ability To Continue As A Going Concern
Athenex Inc reports results for the quarter ended in December - Earnings Summary
Athenex Inc expected to post a loss of 18 cents a share - Earnings Preview
Athenex Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Athenex Announces Appointment Of CFO
Brief: Athenex Announces Agreement With ImmunityBio Regarding Dunkirk Manufacturing Facility
Brief: Athenex Announces UK MHRA Validation Of The Marketing Authorization Application For Oral Paclitaxel And Encequidar For Review
Brief: Athenex Announces Exclusive License Agreement With National Cancer Institute To Utilize T Cell Receptors Targeting Mutated P53, Kras, And Egfr For The Development Of Autologous And Allogeneic Cell Therapies
Athenex Inc reports results for the quarter ended in September - Earnings Summary